Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen

@article{Binkhorst2013UnjustifiedPO,
  title={Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen},
  author={Lisette Binkhorst and Ron H. J. Mathijssen and Myrthe P. P. van Herk-Sukel and Marjolein Bannink and Agnes Jager and Erik A C Wiemer and Teun van Gelder},
  journal={Breast Cancer Research and Treatment},
  year={2013},
  volume={139},
  pages={923-929}
}
Tamoxifen is a largely inactive pro-drug, requiring metabolism into its most important metabolite endoxifen. Since the cytochrome P450 (CYP) 2D6 enzyme is primarily involved in this metabolism, genetic polymorphisms of this enzyme, but also drug-induced CYP2D6 inhibition can result in considerably reduced endoxifen formation and as a consequence may affect… CONTINUE READING